Dracen Pharmaceuticals Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $19.3M

  • Investors
  • 4

Dracen Pharmaceuticals General Information

Description

Developer of glutamine antagonists designed to treat advanced solid tumors. The company's technology leverages immuno-metabolism and tumor-directed delivery to inhibit glutamine metabolism, providing a treatment paradigm that remodels the tumor microenvironment and stimulates immune responses to shrink tumors and extend patient survival.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9276 Scranton Road
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (410)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 9276 Scranton Road
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (410)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dracen Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A1) 10-Aug-2023 $19.3M Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 22-Mar-2018 Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Startup
To view Dracen Pharmaceuticals’s complete valuation and funding history, request access »

Dracen Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Series A
To view Dracen Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Dracen Pharmaceuticals Patents

Dracen Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024006742-A2 Nrf2 protein degraders Inactive 27-Jun-2022
WO-2024006742-A3 Nrf2 protein degraders Inactive 27-Jun-2022
WO-2022261117-A1 Combination therapy with a don prodrug and a tigit inhibitor Inactive 07-Jun-2021
EP-4221842-A1 Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof Pending 02-Oct-2020
EP-4221842-A4 Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof Pending 02-Oct-2020 A61K31/404
To view Dracen Pharmaceuticals’s complete patent history, request access »

Dracen Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dracen Pharmaceuticals Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Deerfield Management Venture Capital Minority
i&i Biotech Fund Venture Capital Minority
i&i Prague Accelerator/Incubator Minority
Johns Hopkins Technology Ventures Accelerator/Incubator Minority
To view Dracen Pharmaceuticals’s complete investors history, request access »

Dracen Pharmaceuticals FAQs

  • When was Dracen Pharmaceuticals founded?

    Dracen Pharmaceuticals was founded in 2016.

  • Where is Dracen Pharmaceuticals headquartered?

    Dracen Pharmaceuticals is headquartered in San Diego, CA.

  • What is the size of Dracen Pharmaceuticals?

    Dracen Pharmaceuticals has 4 total employees.

  • What industry is Dracen Pharmaceuticals in?

    Dracen Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Dracen Pharmaceuticals a private or public company?

    Dracen Pharmaceuticals is a Private company.

  • What is the current valuation of Dracen Pharmaceuticals?

    The current valuation of Dracen Pharmaceuticals is .

  • What is Dracen Pharmaceuticals’s current revenue?

    The current revenue for Dracen Pharmaceuticals is .

  • How much funding has Dracen Pharmaceuticals raised over time?

    Dracen Pharmaceuticals has raised $59.3M.

  • Who are Dracen Pharmaceuticals’s investors?

    Deerfield Management, i&i Biotech Fund, i&i Prague, and Johns Hopkins Technology Ventures have invested in Dracen Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process